3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Urinary Bladder Neoplasms
7
Carcinoma, Transitional Cell
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Ureteral Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Advanced Solid Tumor
1
Advanced Bladder Cancer
1
Interventions
Cisplatin
2
tislelizumab
1
pembrolizumab
1
enfortumab vedotin
1
cabozantinib
1
VMBP protocol
1
Pemetrexed
1
Nivolumab
1
Neoadjuvant Therapy
1
Gemcitabine
1
Docetaxel
1
Carboplatin
1
Administration, Intravesical
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1/2
×
Urologic Neoplasms
×
enfortumab vedotin
×
Clear all
NCT03288545
2026-03-24
EV-103
Astellas Pharma Inc
Phase 1/2
Terminated
348 enrolled
1 FDA